Molecular approaches to lung cancer evaluation

Lung Cancer

Volumn 38, Issue 3 SUPPL., 2002, Pages 9-

  Niklinski, Jacek ^a   Hirsch, Fred R ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Diagnosis; Lung cancer; Molecular techniques; Prognosis

Indexed keywords

BETA TUBULIN; COMPLEMENTARY DNA; DNA; MICROSATELLITE DNA; PROTEIN; PROTEIN P53; RNA;

ARTICLE; ASSAY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CELL ISOLATION; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; MOLECULAR BIOLOGY; MUTATION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 0036895085     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0169-5002(02)00260-x     Document Type: Article

References (71)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics. CA Cancer J. Clin. 51:2001;15-36.
2. Mountain C.F. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest. 108:1995;246-254.
3. Montuenga L.M., Mulshine J.L. New molecular strategies for early lung cancer detection. Cancer Invest. 18:2000;555-563.
4. Mulshine J.L., Henschke C.I. Prospects for lung cancer screening. Lancet. 355:2000;592-593.
5. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7:2001;5-22.
6. Kohno T., Yokota J. How namy tumor suppressor genes are involved in human lung carcinogenesis. Carcinogenesis. 20:1999;1403-1410.
7. Mao L., Lee J.S., Kurie J.M., et al. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89:1997;857-862.
8. Niklinski J., Niklinska W., Chyczewski L., Becker H.D., Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur. J. Cancer Prev. 10:2001;213-226.
9. Rosell R., O'Brate A., Monzo M., et al. Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer. Rev. Oncol. 3:2001;60-71.
10. Sandford A.J., Pare P.D. Direct PCR of small genomic DNA fragments from serum. BioTechiques. 23:1997;890-892.
11. Niklinska W., Chyczewski L., Niklinski J. New molecular approaches to lung cancer: biological and clinical implications of P53, P16 and K-RAS studies. Folia. Histochem. Cytobiol. 39:2001;51-56.
12. Fong K.M., Sekido Y., Minna J.D. Molecular pathogenesis of lung cancer. J. Thorac. Cardiovasc. Surg. 118:1999;1136-1152.
13. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16:1998;1207-1217.
14. Mitsudomi T., Oyama T., Kusano T., et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 85:1993;2018-2023.
15. Niklinska W., Burzykowski T., Chyczewski L., et al. P53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. Eur. J. Cancer Prev. 9:2000;81-87.
16. Tomizawa Y., Kohno T., Fujita T., et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene. 18:1999;1007-1014.
17. Passlick B., Izbicki J.R., Haussinger K., Thetter O., Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 109:1995;1205-1211.
18. De Anta J.M., Jassem E., Rosell R., et al. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene. 15:1997;2951-2958.
19. Tomizawa Y., Kohno T., Fujita T., et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene. 18:1999;1007-1014.
20. Huang C.L., Taki T., Adachi M., et al. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int. J. Oncol. 12:1998;553-563.
21. Vega F.J., Iniesta P., Caldes T., et al. P53 exon 5 mutations as a prognostic indicator of shortened survival in non-small cell lung cancer. Br. J. Cancer. 76:1997;44-51.
22. Monzo M., Rosell R., Sanchez J.J., et al. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J. Clin. Oncol. 17:1999;1786-1793.
23. Cairns P., Sidransky D. Molecular methods for the diagnosis of cancer. Biochim. Biophys. Acta. 1423:1999;C11-C18.
24. Mills N.E., Fishman C.L., Scholes J., et al. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl. Cancer Inst. 87:1995;1056-1060.
25. Koo H.M., Gray-Goodrich M., Kohlhagen G., et al. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J. Natl. Cancer Inst. 91:1999;236-244.
26. Miozzo M., Sozzi G., Musso K., et al. Microsatellilte alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 56:1996;2285-2288.
27. Mao L., Lee D.J., Tockman M.S., et al. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. USA. 91:1994;9871-9875.
28. Zhou X., Kemp B.L., Khuri F.R., et al. Prognostic implication of microsatellilte alteration profiles in early-stage non-small cell lung cancer. Clin. Cancer Res. 6:2000;559-565.
29. Sozzi G., Musso K., Ratcliffe C., et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin. Cancer Res. 5:1999;2689-2692.
30. Rosell R., Taron M., O'Brate A. Predictive molecular markers in non-small cell lung cancer. Curr. Opin. Oncol. 13:2001;101-109.
31. Herman J.G. Hypermathylation of tumor suppressor genes in cancer. Sem. Cancer Biol. 9:1999;359-367.
32. Merlo A., Herman J.G., Mao L., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
33. Richardson B., Yung R. Role of DNA methylation in the regulation of cell function. J. Lab. Clin. Med. 134:1999;333-340.
34. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG island. Proc. Natl. Acad. Sci. USA. 93:1996;9821-9826.
35. Gazzeri S., Gouyer V., Vour'ch C., Brambilla C., Brambilla E. Mechanisms of p16INK4A inactivation in non-small cell lung cancers. Oncogene. 16:1998;497-504.
36. Sekido Y., Fong K.M., Minna J.D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochem. Biophys. Acta. 1378:1998;21-59.
37. Belinsky S.A., Nikula K.J., Palmisano W.A., et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA. 95:1998;11891-11896.
38. Palmisano W.A., Divine K.K., Saccomanno G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60:2000;5954-5958.
39. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
40. Esteller M., Hamilton S.R., Burger P.C., et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:1999;793-797.
41. Esteller M., Sanches-Cespedes M., Rosell R., et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59:1999;67-70.
42. Ahrendt S.A., Chow J.T., Xu L.H., et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl. Cancer Inst. 91:1999;332-339.
43. Lo Y.M.D., Chan L.Y.S., Chan A.T.C., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59:1999;5452-5455.
44. Lo Y.M.D., Chan L.Y.S., Lo K.W., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59:1999;1188-1191.
45. Lo Y.M.D., Wong Y.H.N., Zhang J., et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59:1999;3899-3903.
46. Walch A., Specht K., Smida J., et al. Tissue microdissection techniques in quantitative genome and gene expression analyzes. Histochem. Cell. Biol. 115:2001;269-276.
47. Burchill S.A., Selby P.J. Molecular detection of low-level disease in patients with cancer. J. Pathol. 190:2000;6-14.
48. Kurusu Y., Yamashita J., Ogawa M. Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with non-small cell lung cancer. Surgery. 126:1999;820-826.
49. Salerno C.T., Frizelle S., Niehans G.A., et al. Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction. Chest. 113:1998;1526-1532.
50. Krismann M., Todt B., Schroder J., et al. Low sensitivity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyzes for detection ofhematogenous lung cancer dissemination. J. Clin. Oncol. 13:1995;2769-2775.
51. De Luca A., Pignata S., Casamassimi A., et al. Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin. Cancer Res. 6:2000;1439-1444.
52. Flaman J.M., Frebourg T., Moreau V., et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. USA. 92:1995;3963-3967.
53. Inga A., Cresta S., Monti P., et al. Simple identification of dominant p53 mutations by yeast functional assay. Carcinogenesis. 18:1997;2019-2021.
54. Monzo M., O'Brate A., Sanchez J., et al. Correlation of outcome of resected non-small-cell lung cancer (NSCLC) with p53 mutations detected by yeast functional assay. Lung Cancer. 29:(Suppl. 1):2000;184.
55. Niklinska W., Chyczewski L., Laudanski J., Sawicki B., Niklinski J. Detection of p53 abnormalities in non-small cell lung cancer by yeast functional assay. Folia. Histochem. Cytobiol. 39:2001;147-148.
56. Leung C.S., Lung M.L. Detection of p53 mutations in Hong Kong colorectal carcinomas by conventional PCR-SSCP analysis versus p53 yeast functional assay. Anticancer Res. 19:1999;625-628.
57. Kashiwazaki K., Tonoki H., Tada M., et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene. 15:1997;2667-2674.
58. Fronza G., Inga A., Scott G., et al. The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts. Mutat. Res. 462:2000;293-301.
59. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactoral analysis of p53 alteration in human cancer: a review. Int. J. Cancer. 57:1994;1-9.
60. Kubuschok B., Passlick B., Izbicki J.R., Thetter O., Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small cell lung cancer. J. Clin. Oncol. 17:1999;19-24.
61. Passlick B., Kubuschok B., Izbicki J.R., Thetter O., Pantel K. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann. Thorac. Surg. 68:1999;2053-2058.
62. Tockman M.S., Gupta P.K., Myers J.D., et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J. Clin. Oncol. 6:1988;1685-1693.
63. Zhou J., Mulshine J.L., Unsworth E.J., et al. Purification and characterization of a protein which permits early detection of lung cancer: identification of heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) as the antigen for monoclonal antibody 703D4. J. Biol. Chem. 271:1996;10760-10766.
64. Zhou J., Mulshine J.L., Ro J.Y., et al. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin. Cancer Res. 4:1998;1631-1640.
65. Yershov G., Barsky V., Belgovskiy A., et al. DNA analysis and diagnostics on oligonucleotide microchips. Proc. Natl. Acad. Sci. USA. 93:1996;4913-4918.
66. Eggers M., Hogan M., Reich R.K., et al. A microchip for quantitative detection of molecules utilizing luminescent and radioisotopic reporter groups. BioTechniques. 17:1994;516-525.
67. Schraml P., Kononen J., Bubendorf L., et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res. 5:1999;1966-1975.
68. Bremnes R.M., Veve R., Gabrielson E., Hirsch F.R., et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small cell lung cancer. J Clin Oncol. 20:2002;2417-2428.
69. Wang T., Hopkins D., Schmidt C., et al. Indentification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene. 19:2000;1519-1528.
70. Chen J.J., Peck K., Hong T.M., et al. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res. 61:2001;5223-5230.
71. Hong T.M., Yang P.C., Peck K., et al. Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am. J. Respir. Cell Mol. Biol. 23:2000;355-363.